Antibody-drug conjugates: smart chemotherapeutics
Antibody-drug conjugates (ADCs) have emerged as a promising class of anticancer therapeutics, demonstrating improved precision and reduced off-target toxicity in targeting cancer cells. The development of ADCs involves careful consideration of various components, including target-specific antibodies, cytotoxic payloads, and linkers.
In this article, Sino Biological explores the structure of ADCs, the mechanism of action, the evolution of three generations, clinical success stories, challenges faced, and future directions, including novel payload designs and diverse applications beyond cancer therapy.
Antibody-drug Conjugates Smart Chemotherapeutics
This content was provided by
Follow Sino Biological on LinkedIn and YouTube.
Submit Your Research to the F1000Research Oncology Gateway
Share your oncology research with the global scientific community through the F1000Research Oncology Gateway. With trusted publishing, open access, and transparent peer review, your work will uphold the highest standards of research integrity while driving innovation in cancer treatment and understanding.
Join a trusted platform that accelerates progress in oncology. Submit your research today at F1000Research Oncology Gateway.
